Normacor® is an innovative cardioplegic drug. Designed for performing normothermic open heart surgeries with cardiopulmonary bypass. Actual elimination of ischemia and reperfusion injuries provides a high degree of protection of the heart without limiting the duration of the surgery. It is possible to use the drug under hypothermia.
NORMACOR® belongs to the category of the drugs with proven safety and efficacy. In accordance with the current legislation of the Russian Federation, the drug has passed a comparative clinical study.
NORMACOR® (as the drug and trademark) is protected by the patents of the Russian Federation. The patents are being filed in other countries.
NORMACOR® is the world's only cardioplegic drug developed for normothermic and hypothermic cardioplegia under cardiopulmonary bypass.